Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer
Non-clear cell kidney cancer is a group of different subtypes [...]
Real-world survival outcomes of metastatic papillary and clear cell kidney cancer
In this study, real world data is used to compare [...]
Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer
A recent paper published in The Oncologist has shown that [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
A modified nivolumab/ipilimumab dosing regimen
In this phase 3b/4 study, people with advanced kidney cancer [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
